GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XSGO:GILD) » Definitions » Cyclically Adjusted Revenue per Share

Gilead Sciences (XSGO:GILD) Cyclically Adjusted Revenue per Share : $19.66 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Gilead Sciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Gilead Sciences's adjusted revenue per share for the three months ended in Mar. 2025 was $5.295. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $19.66 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted Revenue Growth Rate was 2.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Gilead Sciences was 47.20% per year. The lowest was 9.00% per year. And the median was 31.75% per year.

As of today (2025-05-29), Gilead Sciences's current stock price is $89.71. Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $19.66. Gilead Sciences's Cyclically Adjusted PS Ratio of today is 4.56.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gilead Sciences was 21.39. The lowest was 2.68. And the median was 4.59.


Gilead Sciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted Revenue per Share Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.74 16.96 16.33 18.93 23.65

Gilead Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.45 23.07 23.09 23.65 19.66

Competitive Comparison of Gilead Sciences's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PS Ratio falls into.


;
;

Gilead Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=5.295/134.9266*134.9266
=5.295

Current CPI (Mar. 2025) = 134.9266.

Gilead Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 5.353 100.684 7.174
201509 5.519 100.392 7.418
201512 5.786 99.792 7.823
201603 5.520 100.470 7.413
201606 5.739 101.688 7.615
201609 5.601 101.861 7.419
201612 5.525 101.863 7.318
201703 4.928 102.862 6.464
201706 5.422 103.349 7.079
201709 4.937 104.136 6.397
201712 4.510 104.011 5.851
201803 3.855 105.290 4.940
201806 4.318 106.317 5.480
201809 4.282 106.507 5.425
201812 4.482 105.998 5.705
201903 4.116 107.251 5.178
201906 4.452 108.070 5.558
201909 4.423 108.329 5.509
201912 4.615 108.420 5.743
202003 4.369 108.902 5.413
202006 4.098 108.767 5.084
202009 5.216 109.815 6.409
202012 5.793 109.897 7.112
202103 5.090 111.754 6.145
202106 4.934 114.631 5.808
202109 5.880 115.734 6.855
202112 5.740 117.630 6.584
202203 5.222 121.301 5.809
202206 4.968 125.017 5.362
202209 5.584 125.227 6.017
202212 5.841 125.222 6.294
202303 5.037 127.348 5.337
202306 5.246 128.729 5.499
202309 5.609 129.860 5.828
202312 5.669 129.419 5.910
202403 5.362 131.776 5.490
202406 5.558 132.554 5.657
202409 6.017 133.029 6.103
202412 5.918 133.157 5.997
202503 5.295 134.927 5.295

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Gilead Sciences  (XSGO:GILD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=89.71/19.66
=4.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gilead Sciences was 21.39. The lowest was 2.68. And the median was 4.59.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Gilead Sciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Industry
Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).